Phaseline

Targets › CDA

CDA (Cytidine deaminase): drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Hematology, Oncology; next expected readout Nov 2027.

This enzyme scavenges exogenous and endogenous cytidine and 2'-deoxycytidine for UMP synthesis. (UniProt, P32320)

Open in Phaseline: the race on CDA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Taiho OncologyCedazuridine
Cytidine deaminase inhibitor
CDAPhase 2Myelodysplastic Syndromes; Solid TumorNov 2027

Conditions

Myelodysplastic Syndromes (1) Solid Tumor (1)

Modalities

small molecule (1)

Companies

Taiho Oncology (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.